Sign in
4

Changes in Ownership

Allogene Therapeutics, Inc. Filed Acc 0001209191-18-055374

President and CEO bought 40,000 shares at $18.00 ($720,000)

  • President and CEO acquired 29,946 shares (conversion)

From the SEC's structured data for this filing

Trades in this filing

Chang David D · President and CEO

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2018-10-15 Purchase : show line 1 in the form +40,000 $18.00 $720,000 1,995,625 D
2018-10-15 Conversion : show line 2 in the form +29,946 1,101,838 I
Open-market purchases · 40,000 sh · avg $18.00 · $720,000

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2018-10-15 Conversion : show line 3 in the form Series A Convertible Preferred Stock −5,704 0 I
Loading xslF345X03/doc4.xml…